- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Remynd N.V.
BioCentury | Sep 4, 2024
Management Tracks
Evers leaving Evotec as CBO
Plus: C-suite changes at Dyne, and updates from Novocure, Amphista, reMYND, Belite Bio, Forward and more
BioCentury | Jun 1, 2024
Discovery & Translation
Science Spotlight: Restoring calcium homeostasis for Alzheimer’s, a gene therapy foam, and more
BioCentury’s roundup of translational innovations
BioCentury | Apr 2, 2024
Product Development
Neurology’s false choice: symptomatic vs. disease-modifying
A new theme in Alzheimer’s is aiming for early symptom relief PLUS long-term disease modification
BioCentury | Jan 21, 2021
Deals
Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda
Preclinical protein degradation play Plexium Inc. raised $35 million in an extension of its series A round and appointed Mike Grey as chairman. The financing, led by Lux Capital and Pivotal
Items per page:
1 - 10 of 18